Riluzole (Rilutek) in Kenya

Product Summary

Riluzole (brand name Rilutek) is a prescription medication used to slow the progression of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. It works by reducing glutamate-mediated motor neuron damage, extending survival by 2–3 months and delaying tracheostomy. Available as 50mg tablets in Kenya, it requires specialist neurologist oversight due to its narrow safety profile.

Composition

• Active Ingredient: Riluzole 50mg per tablet.
• Form: White, film-coated, scored tablets.
• Inactive Ingredients: Lactose, microcrystalline cellulose, magnesium stearate.

Key Uses

• ALS Treatment:
  • Slows disease progression in adults with ALS.
  • Extends time before ventilator dependence.
• Mechanism: Inhibits glutamate release, blocking excitotoxic neuronal damage.

How to Use

Dosing Guidelines

• Standard Dose: 50mg every 12 hours (100mg/day).
• Administration:
  • Take 1 hour before or 2 hours after meals (high-fat food reduces absorption).
  • Swallow whole; do not crush/chew.
• Renal/Hepatic Adjustment:

  Condition	Dose Adjustment
  Mild Hepatic	50mg once daily
  Moderate-Severe	Avoid (risk of toxicity)
  Renal Impairment	No adjustment needed.

Monitoring Requirements

• Liver Function Tests (LFTs):
  • Baseline, then monthly for 3 months, then every 3 months.
  • Stop if ALT/AST >5x ULN (upper limit of normal).
• Blood Counts: Monitor for neutropenia (rare).

Potential Side Effects

Common

• Nausea, fatigue, dizziness, diarrhea.
• Elevated liver enzymes (ALT/AST).

Serious Risks

• Hepatotoxicity:
  • Symptoms: Jaundice, dark urine, abdominal pain.
  • Action: Stop immediately; hospitalize if severe.
• Interstitial Lung Disease: Cough, dyspnea (discontinue if suspected).
• Neutropenia: Increased infection risk (monitor CBC).

Precautions & Interactions

Avoid if:

• History of hypersensitivity to riluzole.
• Active liver disease or elevated baseline transaminases.
• Pregnancy (teratogenic in animals).

Drug Interactions

• CYP1A2 Inhibitors (e.g., ciprofloxacin, fluvoxamine): Avoid (increases riluzole levels → toxicity).
• Hepatotoxic Drugs (e.g., paracetamol, statins): Increased liver injury risk.
• Theophylline: Reduced clearance (monitor levels).

Pregnancy/Breastfeeding

• Category C: Avoid unless benefits outweigh risks.
• Breastfeeding: Discontinue drug or breastfeeding (excreted in milk).

Access & Cost in Kenya

Challenges in Kenya

1. Extreme Cost:
   • Monthly cost exceeds average annual income for most Kenyans.
   • NHIF: No coverage (considered “non-essential”).
2. Limited Access:
   • Only neurologists can prescribe; few outside major cities.
   • Stockouts common; requires advance ordering.
3. Diagnostic Barriers:
   • ALS diagnosis often delayed (requires EMG, neurology consult).
4. Palliative Care Gap:
   • Most patients lack access to multidisciplinary ALS care (ventilators, feeding tubes).

Frequently Asked Questions

1. Is Riluzole available over-the-counter?
   No – prescription-only by neurologists.

2. Does NHIF cover it?
   No – not included in Kenya’s essential medicines list.

3. Are there cheaper alternatives?
   No – riluzole is the only disease-modifying ALS drug. Edaravone (Radicava) is unavailable.

4. Can I split tablets to save costs?
   No – alters absorption; use only full 50mg doses.

5. What if LFTs rise?
   Stop immediately; consult neurologist. May restart at lower dose if normalized.

6. How long should treatment continue?
   Until disease progression outweighs benefits (e.g., ventilator dependence).

Who Can Benefit

• ALS Patients:
  • Within 3 years of symptom onset (greatest benefit).
  • With preserved respiratory function (FVC >60%).
• Exclusions:
  • Advanced disease (ventilator-dependent).
  • Severe liver/kidney disease.

Support Resources

• Neurology Referral Centers:
  • National teaching hospitals (e.g., KNH, MTRH).
  • Private neurology clinics in Nairobi.
• Palliative Care:
  • Kenya Hospices and Palliative Care Association (KEHPCA).
• Patient Groups:
  • ALS Support Kenya (Facebook community).